Opko Expands Prostate Cancer Biomarker Licensing Deal as Part of Commercialization Plan

Mar 23, 2012

Premium

Opko Health said this week that it has expanded a licensing deal with Finnish biotech firm Artic Partners for prostate cancer protein biomarkers that it announced in January (PM 1/30/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

New Nature EIC Talks Transparency

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic Genealogy for Another Arrest

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

This Week in PLOS

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Working With Others

Wired reports that 23andMe is trying to bolster its outside collaborations.

Featured White Papers

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Albumin Removal Reference Applications

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Main menu